Prakt. Lékáren. 2015; 11(3e) [Pediatr. praxi. 2014;15(6):337-339]
Differences in Pharmacokinetics in Children
- 1 Ústav farmakologie LF UP a FN Olomouc
- 2 Lékárna FN Olomouc
Human growth and development consists of a continuum of biologic events. The impact of these developmental changes in drugdisposition is largely related to changes in body composition (e.g. body water content, plasma protein concentrations) and functionof organs important in metabolism (e.g. the liver) and excretion (e.g. the kidney). During the first decade of life, these changes aredynamic and can be nonlinear and discordant making standardized dosing inadequate. During rapid phases of growth/developmentdrug disposition and response may be altered. The main goal is to optimize drug therapy in children. This can be achieved throughfundamental understanding of how ontogeny influences pharmacokinetics.
Keywords: children, pharmacokinetics, absorption, distribution, excretion
Received: February 1, 2018; Accepted: February 19, 2018; Prepublished online: February 19, 2018; Published: August 1, 2015 Show citation
References
- Yaffe SJ, Aranda JV. Neonatal and Pediatric Pharmacology. 4th Edition. Philadelphia: Lippincott Williams & Wilkins, 2011.
- Rodbro P, Krasilnikoff PA, Christiansen PM. Parietal cell secretory function in early childhood. Scand J Gastroenterol. 1967; 2: 209-213.
Go to original source... 
Go to PubMed... - Koren G. Therapeutic drug monitoring principles in the neonate. National Academy of Clinical Biochemistry. Clin Chem. 1997; 43(1): 222-227. Go to original source...
- Silvers J, Poole JW. Serum concentrations of ampicillin in newborn infants after oral administration. Pediatrics 1973; 51: 578-580. Go to original source... Go to PubMed...
- Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 2003; 18; 349(12): 1157-1167. Go to original source... Go to PubMed...
- Amato M, Huppi P, Isenschmid M, Schneider H. Developmental aspects of percutaneous caffeine absorption in premature infants. Am J Perinatol. 1992; 9: 431-434. Go to original source... Go to PubMed...
- Seyberth HW, Rane A, Schwab M. Pediatric Clinical Pharmacology. Heidelberg: Springer, 2011. Go to original source...
- Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev. 2003; 55(5): 667-686. Go to original source... Go to PubMed...
- Ehrnebo M, Agurell S, Jalling B, Boréus LO. Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Eur J Clin Pharmacol. 1971; 3(4): 189-193. Go to original source... Go to PubMed...
- Lin JH, Yamazaki M. Role of P-glycoproteinin pharmacokinetics: clinical implications. Clin Pharmacokinet 2003; 42: 59-98. Go to original source... Go to PubMed...
- Tsai C, Ahdab-Barmada M, Daood MJ,Watchko JF. P-glycoprotein expression inthe developing human central nervous system:cellular and tissue localization. Pediatr Res 2001; 47: Suppl: 436A.
- Van den Anker JN, Schoemaker RC, Hop WC, van der Heijden BJ, Weber A, Sauer PJ, Neijens HJ, de Groot R. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. Clin Pharmacol Ther. 1995; 58(6): 650-659. Go to original source... Go to PubMed...
- Johnson TN. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology. 2003; 192(1): 37-48. Go to original source... Go to PubMed...
- Brion LP, Fleischman AR, Schwartz GJ. Gentamicin interval in newborn infants as determined by renal function and postconceptional age. Pediatr Nephrol. 1991; 5(6): 675-679. Go to original source... Go to PubMed...